Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 1997Journal of Clinical Oncology

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDG MaloneyCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaAGA.J. Grillo-LópezThe University of Texas MD Anderson Cancer CenterDBDavid BodkinAstraZeneca (United Kingdom)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Maloney et al. (1997) studied this question.

synapsesocial.com/papers/6a105e2ed478ddac0ffcc972https://doi.org/10.1200/jco.1997.15.10.3266
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma1994 · 756 citations
  2. 2Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation1984 · 695 citations
  3. 3Isolated human follicular dendritic cells display a unique antigenic phenotype.1989 · 221 citations
  4. 4Role of the Bp35 cell surface polypeptide in human B-cell activation.1985 · 170 citations
  5. 5Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody1993 · 552 citations